KisoJi Leadership Team

KisoJi is led by an experienced and entrepreneurial management team with a successful track record in antibody development, oncology, and life science finance / business development.

David S. Young, M.D.

Co-Founder and C.E.O.

Dr. Young is the C.E.O., C.S.O., and co-founder of KisoJi. Previously, he was the founder, C.S.O. and C.E.O. of ARIUS Research Inc., a publicly-traded biotechnology company developing therapeutic cancer antibodies and sold to Roche in 2008. ARIUS had secured partnerships with leading companies such as Genentech, Takeda Pharmaceuticals, and Protein Design Labs.

Read More

Michael Dixon, CPA, CA


Michael Dixon has over 20 years of experience working in an executive role for venture-backed companies including CFO of GeminX Pharmaceuticals which was acquired by Cephalon in 2011. More recently, Mr Dixon has been CFO or acting CFO for other venture backed pharmaceutical companies including DalCor Pharmaceuticals.

Read More

Luis da Cruz, Ph.D.

Vice President, Research

Dr. da Cruz has more than 16 years of experience in therapeutic antibody discovery and development, having led projects as a scientist and in management responsibilities, both in antibody and drug development from discovery to late clinical stage. Dr. da Cruz initiated his career as a Product Development scientist at MDS-SCIEX, in the development of label-free technologies for drug discovery.

Read More

Gordon Ngan, M.B.A., CFA

Vice President, Business Development

Mr. Ngan has over 20 years of experience in life sciences, with a wealth of fundraising and global business development success across biotech startups and venture-backed companies, through to large publicly traded biotechnology and pharmaceutical companies.   Mr. Ngan has directly led or facilitated over $1 billion in financing and partnership transactions.

Read More